DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/6cb6w5/opportunityanalyze) has announced the addition of the "Opportunity Analyzer: Acute Ischemic Stroke - Opportunity Analysis and Forecasts to 2017" report to their offering.
The acute ischemic stroke (AIS) therapeutics market generated $531m in 2012 across the six major markets (US, France, Germany, Italy, Spain, and UK). By the end of the forecast period in 2017, the market is expected to reach $1.2 billion in sales, growing at a compound annual growth rate (CAGR) of 17.3%. The US market will continue to generate the vast majority of sales due to having the highest prevalence and incidence of ischemic stroke, and comparatively high AIS therapy prices.
Major drivers of growth for the AIS therapeutics market are:
- The launch of desmoteplase, a novel next-generation thrombolytic, which has an extended therapeutic time window compared with the current standard of care, Activase/Actilyse.
- The increasing prominence of telemedicine, which will enhance accessibility to vital stroke care and treatment.
- The rapidly growing and aging population, which will result in a higher incidence of AIS as age is a major risk factor for stroke.
Major barriers to growth are:
- Stringent eligibility criteria for thrombolysis treatment, as well as a narrow therapeutic time window, which means the majority of AIS patients are currently not treated with Activase/Actilyse.
- Impending patent expiry to Activase/Actilyse during the forecast period (2015 and 2016 in the US and 5EU, respectively).
- Clinical trials attrition in the late-stage pipeline, which continues to hamper R&D efforts to bring new novel therapies to market, meaning AIS patients are still restricted to few effective treatment options.
The Development of New Therapies for AIS Remains Challenging
There are many barriers associated with AIS clinical trials that need to be overcome in order to yield greater future trial success. A fundamental challenge with both reperfusion and neuroprotective trials design is stroke heterogeneity.
Most late-stage clinical trials conducted in the US and Europe to date, including all Phase III trials of neuroprotective agents for AIS, have been negative due to unrealistic study endpoints; in fact, there is currently limited agreement on what constitutes a minimally important treatment effect in AIS trials.
Other common issues in such trials, which will require more robust consideration for future studies, include testing drugs too long after stroke onset, and poor patient selection for trials; for example, the inclusion of too many severe or mild patients makes it difficult to detect any treatment effect, or the inclusion of lacunar stroke patients when there is no preclinical evidence that the drug is effective for protection of white brain matter.
Key Topics Covered:
List of Tables
List of Figures
Current Treatment Options
Unmet Needs Assessment and Opportunity Analysis
Pipeline Valuation Analysis
For more information visit http://www.researchandmarkets.com/research/6cb6w5/opportunityanalyze
About Research and Markets
Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.